Idiopathic and recurrent thromboembolic phenomena in cancer patients

Clinical and Translational Oncology

Volumn 10, Issue 10, 2008, Pages 665-669

  López Gómez, Miriam ^a   Gómez Raposo, César ^a   Moyano, María Sereno ^a   Casado Sáenz, Enrique ^a   Batlle, Jaime Feliú ^b   Ruipérez, Carolina Ortega ^c   Barón, Manuel González ^b  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Cancer screening; Idiopathic venous thromboembolism; Low molecular weight heparins; Thromboembolism phenomena; Thrombosis recurrences

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ARTICLE; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM; RECURRENT DISEASE; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; RECURRENCE; VENOUS THROMBOEMBOLISM;

EID: 58149392634     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0268-8     Document Type: Article

References (46)

1. Levitan N, Dowlati A, Remick SC et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine 78:285-291
2. Gouin-Thibaut I, Samama MM (2000) Venous thrombosis and cancer. Ann Biol Clin (Paris) 58:675
3. Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107:17-21
4. Heit JA, Silversteint MD, Mohr DN et al (2002) Risk factors for deep vein thrombosis and pulmonary embolism: a population based case control study. Arch Intern Med 162:1245-1248
5. Levitan N, Dowlati A, Remick SC et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78:285-291
6. Rickles FR, Edwards R (1983) Activation of blo-od coagulation in cancer: Trousseau's syndrome revisited. Blood 62:14-31
7. Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488
8. Prandoni P, Lensing AWA, Cogo A et al (1996) The long term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1-7
9. Kirwan CC, Nath E, Byrne GJ, McCollum CN (2003) Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. BMJ 327:597-598
10. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850
11. Thompson CM, Rodgers RL (2004) Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Chest 126:338S-400S
12. Blom JW, Doggen CJ, Osanto S et al (2005) Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA 293:715-722
13. Caine GJ, Stonelake PS, Lip GY et al (2002) The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 4:465-473
14. Edwards RL, Siver J, Rickles FR (1993) Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 69:205-213
15. Zuckerman E, Touli E, Golan TD et al (1995) Increased thromboembolic incidence in anticardiolipin-positive patients with malignancy. Br J Cancer 72:447-451
16. Sorensen HT, Mellemkjaer L, Steffensesn FH et al (1998) The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338:1169-1173
17. Oktar GL, Ergul EG, Kiziltepe U (2007).Occult malignancy in patients with venous thromboembolism: risk indicators and a diagnostic screening strategy. Phlebology 22:75-79
18. Piccioli A, Lensing AWA, Prins MH (2001) Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2:884-889
19. White RH, Zhow H, Romano PS (2003) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90:446-455
20. Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975-980
21. Geerts WH, Heit JA, Clagett GP et al (2001) Prevention of venous thromboembolism. Chest 119: 132-175S 22.
22. Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975-980
23. Petralia GA, Kakkar AK (2007) Treatment of venous thromboembolism in cancer patients. Semin Throm Haemostasia 33:701-711
24. Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488
25. Shah MA, Ilson D, Kelsen DP (2005) Thromboembolic events in gastric cancer: High incidence in patients receiving irinotecan and bevacizumab based therapy. J Clin Oncol 23:2574-2576
26. Cavo M, Zamagni E, Cellini C et al (2002). Deep vein thrombosis in patients with multiple myeloma receiving first line thalidomide dexamethasone therapy. Blood 100:2272-2273
27. Kuenen BC, Levi M, Meijiers JC et al (2003) Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU 5416. J Clin Oncol 21:2192-2198
28. Wun T, Law L, Harvey D et al (2003) Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation and erythropoietin. Cancer 98:1514-1520
29. Bokemeyer C, Aapro MS, Courdi A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258-270
30. Hutten B, Prins M, Gent M et al (2000) Incidence of recurrent thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18: 3078-3083
31. Ansell J, Hirsh J, Poller L et al (2004) The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest 126[3 Suppl]:204S-233S
32. Lee AY, Levine MN, Baker RI et al (2003) Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146-153
33. Meyer G (2008) Do anticoagulants improve survival in patients with cancer? Pathol Biol 56:233-238
34. Kakkar AK (2005) LMWH and survival in patients with malignant disease. Cancer Control 12 [Suppl 1]:22-30
35. Folkman J, Weisz PB, Joullie MM et al (1989) Control of angiogenesis with synthetic heparin substitutes. Science 243:1490-1493
36. Vlodavsky I, Friedmann Y, Elkin M et al (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5:793-802
37. Nasir FA, Patel HK, Scully MF et al (2003) The low molecular weight heparin dalteparin sodium inhibits angiogenesis and induces apoptosis in an ex-perimental tumour model. Blood 102 (11) Abstract
38. Borsing L, Wong R, Feramisco J et al (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectine, carcinoma mucins and tumor metastasis. Proc Natl Acad Sci USA 98:3352-3357
39. Akl EA, Kamath G, Yosuico V et al (2008) Throm boprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer 112:2483-2492
40. Reichart P, Kretzchmar A, Biakhov M et al (2002) A phase III double blind placebo controlled study evaluating the efficacy and safety of daily low molecular weight heparin (dalteparin sodium, Fragmin) in preventing catheter related complications in cancer patients with central venous catheters. Proc Annu Meet Am Soc Clin Oncol 21:1474
41. Hutten BA, Prins MH, Gent M et al (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18:3078-3083
42. Schwartz RN (2005) Considerations and challenges with existing treatments for thrombosis in cancer patients. Am J Health Syst Pharm 62[22 Suppl 5]:S7-9
43. Noble S (2007) The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgrad Med J 83:671-674
44. Lyman GH, Khorana AA, Falange A et al (2007) American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505
45. Camps C, Juárez V, Iranzoa J et al (2007) Venous thromboembolic disease in cancer. Optimisation of the use of antithrombotic agents. Clin Transl Oncol 9:161-171
46. Levine M, Hirsh J, Gent M, Arnol A et al (1994) Double blind randomised trial of a very low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889